关注
Monica Marta
Monica Marta
Barts Health NHS Trust and Blizard Institute/ QMUL, London
在 qmul.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ...
Neurology 64 (7), 1144-1151, 2005
10682005
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
G Giovannoni, B Turner, S Gnanapavan, C Offiah, K Schmierer, M Marta
Multiple sclerosis and related disorders 4 (4), 329-333, 2015
3842015
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ...
Multiple Sclerosis Journal 21 (8), 1013-1024, 2015
3752015
T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived …
M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ...
The Journal of Immunology 172 (11), 7169-7176, 2004
3182004
Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis
D Baker, M Marta, G Pryce, G Giovannoni, K Schmierer
EBioMedicine 16, 41-50, 2017
2642017
Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis
M Marta, Å Andersson, M Isaksson, O Kämpe, A Lobell
European journal of immunology 38 (2), 565-575, 2008
2472008
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients
MI Leite, E Coutinho, M Lana-Peixoto, S Apostolos, P Waters, D Sato, ...
Neurology 78 (20), 1601-1607, 2012
2382012
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
D Baker, CAK Roberts, G Pryce, AS Kang, M Marta, S Reyes, K Schmierer, ...
Clinical & Experimental Immunology 202 (2), 149-161, 2020
2042020
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
J Pakpoor, G Disanto, DR Altmann, S Pavitt, BP Turner, M Marta, ...
Neuroimmunology & Neuroinflammation 2 (6), e158, 2015
1462015
The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis.
D Baker, G Pryce, LK James, M Marta, K Schmierer
Multiple Sclerosis and Related Disorders, 102279, 2020
962020
Regulation of autoimmune encephalomyelitis by toll-like receptors
M Marta, UC Meier, A Lobell
Autoimmunity reviews 8 (6), 506-509, 2009
962009
Sex effects across the lifespan in women with multiple sclerosis
KM Krysko, JS Graves, R Dobson, A Altintas, MP Amato, J Bernard, ...
Therapeutic advances in neurological disorders 13, 1756286420936166, 2020
772020
Toll‐like receptors in multiple sclerosis mouse experimental models
M Marta
Annals of the New York Academy of Sciences 1173 (1), 458-462, 2009
722009
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
D Hunt, G Giovannoni
Practical neurology 12 (1), 25-35, 2012
662012
Protecting people with multiple sclerosis through vaccination
S Reyes, M Ramsay, S Ladhani, G Amirthalingam, N Singh, C Cores, ...
Practical neurology 20 (6), 435-445, 2020
632020
Biomarker report from the phase II lamotrigine trial in secondary progressive MS–neurofilament as a surrogate of disease progression
S Gnanapavan, D Grant, S Morant, J Furby, T Hayton, CE Teunissen, ...
PloS one 8 (8), e70019, 2013
622013
The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population
AM Silva, C Pereira, A Bettencourt, C Carvalho, AR Couto, MI Leite, ...
Journal of the neurological sciences 258 (1-2), 69-74, 2007
622007
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
G Giovannoni, M Marta, A Davis, B Turner, S Gnanapavan, K Schmierer
Practical neurology 16 (5), 389-393, 2016
542016
Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?
AH Maghzi, M Marta, I Bosca, M Etemadifar, R Dobson, C Maggiore, ...
Pathophysiology 18 (1), 13-20, 2011
462011
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats
G Castelo-Branco, P Stridh, AO Guerreiro-Cacais, MZ Adzemovic, ...
Neurobiology of disease 71, 220-233, 2014
412014
系统目前无法执行此操作,请稍后再试。
文章 1–20